CRISPLD2 protects against liver inflammation and fibrosis via GRP78 to repress HMGB1/TLR4 axis–mediated STING palmitoylation

Hepatology Communications · Published 2026-04-24 · DOI 10.1097/hc9.0000000000000954

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1097/hc9.0000000000000954

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Neoadjuvant therapy in primary liver cancer: From the missing piece to a new paradigm · Hepatology Communications · 2026 · Same journal
• Prospective validation of a real-time natural language processing pipeline for the extraction of elastography results from electronic health record data · Hepatology Communications · 2026 · Same journal
• Reply: High mortality at safety-net hospitals for patients with cirrhosis · Hepatology Communications · 2026 · Same journal
• Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH · Hepatology Communications · 2026 · Same journal
• Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies · Hepatology Communications · 2026 · Same journal
• IL15-mediated crosstalk between LSECs and CD8⁺ tissue-resident memory T cells drives alcohol-associated hepatitis · Hepatology Communications · 2026 · Same journal
• Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study · Hepatology Communications · 2026 · Same journal
• Contemporary global epidemiology of cirrhosis · Hepatology Communications · 2026 · Same journal
• The role of ammonia in chronic liver disease · Hepatology Communications · 2026 · Same journal
• The contemporary epidemiology, causes, and management of drug-induced liver injury · Hepatology Communications · 2026 · Same journal